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Abstract  
Perinatal-lethal Gaucher disease is very rare and is considered a variant of type 2 Gaucher disease that occurs in the neonatal period. The most 
distinct features of perinatal-lethal Gaucher disease are non-immune hydrops fetalis. Less common signs of the disease are hepatosplenomegaly, 
ichthyosis and arthrogryposis. We report a case of Gaucher's disease (type 2) diagnosed in a newborn who presented with Hydrops Fetalis. 
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Introduction 
 
Gaucher disease (GD), is an autosomal recessive lysosomal storage 
disorder, caused by a deficiency in the enzyme glucocerebrosidase. 
It is the most common of the lysosomal storage disorders. Type 2 
GD, the most severe and progressive form, manifests either 
prenatally or in the first months of life [1]. Perinatal-lethal GD is 
very rare and is considered a variant of type 2 GD. The most distinct 
features are non-immune hydrops fetalis [2,3]. We report a case of 
type 2 Gaucher's disease diagnosed in a newborn who presented 
with hydrops fetalis. 
  
  
Patient and observation 
 
The patient, a female newborn, was the second infant from a 31 
year-old gravida 2 para 2 mother. The maternal past medical history 
included a previous preterm male stillborn with undiagnosed case of 
non-immune hydrops fetalis. Family history revealed also two 
undiagnosed cases of hydrops fetalis in two preterm stillbirths. Third 
trimester fetal ultrasonography revealed severe hydrops fetalis with 
skin edema, polyhydramnios, hepatomegaly, clustered bowel loops, 
and fetal hypokinesia. Maternal prenatal tests showed blood type A, 
Rh +, negative maternal serum indirect Coombs test, immunity to 
rubella and negative serology results for toxoplasma, hepatitis 
surface antigen and cytomegalovirus. The infant was delivred by 
cesarean section indicated for breech presentation and 
polyhydramnios, at 36 weeks of gestation. Apgar scores of 2 and 3 
at 1 and 5 minutes, respectively. Body weight was 2600gm 
(39th percentile), length was 44 cm (10th percentile), and head 
circumference was 34 cm (82thpercentile). At birth, she was apneic 
and required endotracheal intubation. 
 
Physical examination revealed a state of hydrops with generalized 
skin edema, thickened and shiny skin, hepatosplenomegaly, 
hypertonia, arthrogryposis and akinesia. No Dysmorphic facial 
features or other congenital anomalies were associated (Figure 1). 
Chest radiograph showed an enlarged cardiac silhouette (Figure 2). 
Laboratory results included blood type A, Rh +, negative direct 
Coombs test, a normal blood cell count. Bacterial and viral cultures 
are negative, SGOT / SGPT: 237/22U/L. Urinary screening for 
metabolic disorders was negative. Specific tests was as follows: low 
glucocerebrosidase enzymatic activity on leucocytes (patient level 
=0.4 nmol/h/mg, controls=20 nmol/h/mg); and high serum 
chitotriosidase level (patient=16 200 nmol/h/ml, controls 200 
nmol/h/ml). Parent's measurement of glucocerebrosidase enzymatic 
activity on leucocytes showed results consistent with a heterozygous 
for GD. The infant died on the first day of life after stopping 
resuscitation. Diagnosis was confirmed by direct sequencing of 
glucose rebrosidase gene (GBA). A single nucleotide substitution 
was found in exon 9: c.1255G>A leading to the substitution of 
Aspartic Acid by Asparagine (p.Asp419Asn). This diagnosis has 
allowed two prenatal diagnoses for the next pregnancies. The 





Hydrops fetalis, has been associated with several lysosomal storage 
disorders, including Type 2 GD [3]. Cases involving hydrops tend to 
be perinatal lethal disorders and the pathophysiology is not well 
understood [4]. Generally, when hydrops is present in Type 2 GD, 
the fetus dies in utero, or is delivered prematurely and dies within 
the first days of life [5]. In our case, there were three family 
histories of undiagnosed perinatal death in the same circunstances. 
Our patient was intubated and maintainded under mechanical 
ventilation just to perform laboratory tests and enzymes studies, 
necessary to inform future pregnancies. When a lysosomal storage 
disease is suspected in a fetus or a new born because of hydrops 
fetalis or neonatal hepatosplenomegaly, the presence of 
arthrogryposis and ichthyosis should raise suspicion for GD. In our 
case, the infant had a shiny and thickened skin, reminiscient of a 
collodion-baby phenotype. This finding may have potential 
diagnostic importance. Patients with Type 2 GD exhibit epidermal 
abnormalities regardless of whether ichthyosis is clinically evident 
[5, 6]. The most reliable diagnostic methods are measurement of 
glucose rebrosidase enzymatic activity and direct sequencing of 
GBA1. Enzymatic assays can be performed on leukocytes, 
fibroblasts, or tissue samples such as liver or spleen. Genetic testing 
for GD by direct sequencing of GBA1 can be used to determine 
disease and carrier status [7]. The occurrence of an index case 
invites to offer genetic counselling to parents. Unusual mechanisms 
including de novo mutations have been described in patients with 
GD [8]. Thus the recurrence risk is not always obvious. In the 
presented case, the parents were heterozygous for GD, with a 
significant risk of recurrence of the disease in their offspring. The 
diagnosis has allowed genetic counselling in the next pregnancy. 
  
Page number not for citation purposes 3 
Conclusion 
 
A greater physician awareness of hydrops fetalis as a possible 
clinical presentation of GD will allow early recognition and therefore 
prompt diagnosis, moreover it will allow better estimation of the 
incidence of this disease. An accurate and timely diagnosis of GD is 
critical for genetic counselling, patient and family management that 










All authors have read and agreed to the final version of this 
manuscript and have equally contributed to its content and to the 





We thank Catherine Caillaud for technical assistance in molecular 
analysis. Written consent for publication was obtained from the 





Figure 1: Neonatal presentations of Gaucher disease demonstrating 
hydrops, peeling and shiny skin 
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Figure 1: Neonatal presentations of Gaucher disease demonstrating hydrops, peeling 





Figure 2: Chest radiograph showing an enlarged cardiac silhouette 
 
